Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-14-007643
Filing Date
2014-10-31
Accepted
2014-10-31 15:45:40
Documents
9
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0914_actiniumpharma.htm 10-Q 375399
2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNT f10q0914ex31i_actiniumpharma.htm EX-31.1 13054
3 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND ACCOUNT f10q0914ex32i_actiniumpharma.htm EX-32.1 5712
  Complete submission text file 0001213900-14-007643.txt   4547684

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE atnm-20140930.xml EX-101.INS 531931
5 XBRL SCHEMA FILE atnm-20140930.xsd EX-101.SCH 60286
6 XBRL CALCULATION FILE atnm-20140930_cal.xml EX-101.CAL 24479
7 XBRL DEFINITION FILE atnm-20140930_def.xml EX-101.DEF 218004
8 XBRL LABEL FILE atnm-20140930_lab.xml EX-101.LAB 478055
9 XBRL PRESENTATION FILE atnm-20140930_pre.xml EX-101.PRE 311765
Mailing Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036
Business Address 546 5TH AVENUE, 14TH FLOOR NEW YORK NY 10036 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 141186552
SIC: 2834 Pharmaceutical Preparations